Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SUN PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
SUN PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,072 | 314 | - | |
Low | Rs | 790 | 226 | - | |
Sales per share (Unadj.) | Rs | 182.9 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 35.7 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 46.2 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 11.50 | 0 | - | |
Avg Dividend yield | % | 1.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 233.4 | 73.3 | - | |
Shares outstanding (eoy) | m | 2,399.34 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.1 | 2.9 | 175.9% | |
Avg P/E ratio | x | 26.1 | -11.5 | -227.2% | |
P/CF ratio (eoy) | x | 20.1 | -13.9 | -145.3% | |
Price / Book Value ratio | x | 4.0 | 3.7 | 108.2% | |
Dividend payout | % | 32.2 | 0 | - | |
Avg Mkt Cap | Rs m | 2,233,361 | 45,603 | 4,897.4% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 82,960 | 2,862 | 2,898.6% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 438,857 | 15,761 | 2,784.4% | |
Other income | Rs m | 8,199 | 110 | 7,428.1% | |
Total revenues | Rs m | 447,055 | 15,872 | 2,816.7% | |
Gross profit | Rs m | 112,900 | -2,731 | -4,133.5% | |
Depreciation | Rs m | 25,294 | 680 | 3,718.4% | |
Interest | Rs m | 1,720 | 427 | 402.9% | |
Profit before tax | Rs m | 94,084 | -3,728 | -2,523.6% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 8,476 | 233 | 3,638.4% | |
Profit after tax | Rs m | 85,608 | -3,971 | -2,155.6% | |
Gross profit margin | % | 25.7 | -17.3 | -148.5% | |
Effective tax rate | % | 9.0 | -6.2 | -144.2% | |
Net profit margin | % | 19.5 | -25.2 | -77.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 398,619 | 11,544 | 3,453.1% | |
Current liabilities | Rs m | 199,064 | 6,495 | 3,064.9% | |
Net working cap to sales | % | 45.5 | 32.0 | 142.0% | |
Current ratio | x | 2.0 | 1.8 | 112.7% | |
Inventory Days | Days | 147 | 111 | 132.6% | |
Debtors Days | Days | 95 | 124 | 76.8% | |
Net fixed assets | Rs m | 376,960 | 6,729 | 5,602.2% | |
Share capital | Rs m | 2,399 | 73 | 3,278.8% | |
Net worth | Rs m | 559,954 | 12,371 | 4,526.4% | |
Long term debt | Rs m | 0 | 4,347 | 0.0% | |
Total assets | Rs m | 775,794 | 23,369 | 3,319.7% | |
Interest coverage | x | 55.7 | -7.7 | -720.4% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 83.9% | |
Return on assets | % | 11.3 | -15.2 | -74.2% | |
Return on equity | % | 15.3 | -32.1 | -47.6% | |
Return on capital | % | 17.1 | -19.8 | -86.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 49,593 | 1,345 | 3,686.3% | |
From Investments | Rs m | -79,437 | -413 | 19,230.3% | |
From Financial Activity | Rs m | 23,761 | 3,945 | 602.2% | |
Net Cashflow | Rs m | 1,155 | 4,878 | 23.7% |
Compare SUN PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SUN PHARMA With: SHAMROCK IND MERCURY LAB. HIKAL. PHAARMASIA IND SWIFT LA
Asian stocks fell on Thursday as disappointing earnings forecasts from Facebook parent Meta Platforms hammered tech shares, while the yen's slump past 155 per dollar.